AgingResearch.NewsJoin free

eGenesis

CompanyUnited States

eGenesis develops one asset, in phase 1 (EGEN-2784 in end-stage kidney disease). Mostly cell therapy; based in the United States.

1
Asset
Furthest stage
Phase 1
0
Trials
0
Signals

Pipeline

1

  • EGEN-2784

    Gene-edited porcine kidney with glycan xenoantigen deletions, PERV inactivation, and seven human transgenes for xenotransplantation.

    Phase 1, Cell therapy, end-stage kidney disease

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Similar companies6

Papers

Intelligence